Aurinia Pharmaceuticals

Aurinia fell about 2% in after-hours trading after announcing a patent settlement with Teva concerning a generic version of voclosporin. Teva may launch its generic in the US no earlier than Dec. 7, 2036, unless certain contingencies occur earlier, and acknowledges two US Aurinia patents as enforceable that expire in Dec. 2037. Teva’s marketing remains dependent on FDA approval; further patent suits against other manufacturers are ongoing. » Więcej na de.investing.com

Aurinia Pharmaceuticals has completed the acquisition of Kezar Life Sciences after the expiry of a takeover offer and acquired approximately 80.24% of the outstanding common shares. Kezar shareholders received US$6.955 in cash per share plus a contingent value right (CVR) providing for possible future payments. Aurinia merged Kezar into a subsidiary, making Kezar a wholly owned subsidiary; the merger was effected under Section 251(h) of the Delaware General Corporation Law without a separate shareholder vote. Options with exercise prices below the cash offer vested immediately and were converted into cash payments plus the CVR, while options with exercise prices above the offer were cancelled without replacement. » Więcej na de.investing.com

Aurinia reported Q4 2025 EPS of $1.53 versus an expected $0.15, outperforming estimates by 920%. Revenue rose 29% to $77.1 million, with LUPKYNIS accounting for 95.7% of sales. Pre‑tax net income climbed sharply to $210.8 million, supported by the reversal of allowances on deferred tax assets. For 2026, Aurinia expects net product sales for LUPKYNIS of $305–315 million and emphasizes pipeline development, notably Aritinercept, while noting continued high product concentration risk. » Więcej na de.investing.com